4.3 Article

25-Hydroxyvitamin D Levels and Hypertension Rates

期刊

JOURNAL OF CLINICAL HYPERTENSION
卷 13, 期 3, 页码 170-177

出版社

WILEY
DOI: 10.1111/j.1751-7176.2010.00408.x

关键词

-

资金

  1. Novartis Pharmaceuticals
  2. Genzyme Biotechnology
  3. Kaiser Permanente Southern California Medical Group

向作者/读者索取更多资源

Vitamin D deficiency has been linked to cardiovascular disease and risk factors including hypertension. The authors sought to determine prevalence rates of hypertension in adults tested for 25-hydroxyvitamin D categorized by their levels and evaluate odds ratios for hypertension at lower 25-hydroxyvitamin D levels compared with optimal levels. A cross-sectional study was conducted January 1, 2004, through December 31, 2006, of patients aged 18 years and older within a large ethnically diverse population. Diagnosis of hypertension was determined by International Statistical Classification of Diseases and Related Health Problems codes. Patients were categorized into quartiles according to 25-hydroxyvitamin D levels: ideal (>= 40 ng/mL), adequate (30-39 ng/mL), deficient (15-29 ng/mL), and severely deficient (< 15 ng/mL). Prevalence rates of hypertension and odds ratios were calculated for each 25-hydroxyvitamin D quartile, adjusting for age, sex, race, and renal insufficiency. A total of 2722 individuals met the inclusion criteria for the study. The overall prevalence of hypertension in the study population was 24%. Hypertension rates were 52%, 41%, 27%, and 20% in 25-hydroxyvitamin D quartiles < 15 ng/mL, 15 to 29 ng/mL, 30 to 39 ng/mL, and >= 40 ng/mL, respectively (P <.001). Odds ratios (95% confidence intervals) for hypertension adjusting for age, sex, race, and renal insufficiency were 2.7 (1.4-5.2), 2.0 (1.5-2.6), and 1.3 (1.2-1.6) for 25-hydroxyvitamin D levels < 15 ng/mL, 15 to 29 ng/mL, and 30 to 39 ng/mL, respectively, compared with the >= 40 ng/mL group. This study demonstrates increased rates of hypertension in individuals who tested for lower levels of 25-hydroxyvitamin D starting at levels < 40 ng/mL. This retrospective analysis raises the question of whether supplementing to optimal vitamin D levels can prevent or improve hypertension. J Clin Hypertens (Greenwich). 2011;13:170-177. (C) 2010 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据